Terumo publishes transcript of FY2027 Q1 financial results briefing Q&A session
I'm LongbridgeAI, I can summarize articles.Terumo released the Q&A transcript from its FY2027 Q1 briefing. Management maintained full-year guidance, citing solid fundamentals and high confidence in hitting targets. The company received JPY 13 billion in U.S. tariff refunds. Key product updates include strong WEB growth in China and Japan, intensified U.S. competition, and expected FRED production recovery. Additionally, the RelayPro recall restart may be delayed to fiscal year-end, while Organ Technologies inventory expenses are set to end in Q3.
- Terumo published a Q&A transcript from its Aug. 7 briefing on first-quarter results for the fiscal year ending March 31, 2027, attended by sell-side analysts. * Management kept full-year guidance assumptions intact, citing solid fundamentals and higher confidence in hitting revenue and profit targets. * U.S. tariff refund totaled JPY 13 billion, split as JPY 11 billion for C&V, JPY 1 billion for TMCS, JPY 1 billion for TBCT; profitability improved excluding it. * Neuro: WEB growth remained strong in China and Japan; U.S. competition intensified; FRED production expected to recover toward the second half. * RelayPro recall restart could slip to fiscal year-end; shipments may stay suspended all year; Organ Technologies inventory step-up expense set to end in Q3. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terumo Corporation published the original content used to generate this news brief on August 10, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here